Rutherford Cancer Genetics Receives a Patent for Kidney Cancer Diagnosis
Published By : 25 Nov 2013 |Published By : QYRESEARCH
Rutherford-based Cancer Genetics Inc. grants a patent for the kidney cancer diagnosis. This is known to be the sixth leading type of cancer found among men in the United States.
The acclaimed patent covers a host of Cancer Genetics probes that employ patent methods to test, detect, and/or differentiate several forms of kidney cancer. This patent is officially granted by the United States Patent and Trademark Office.
In addition, the cancer diagnostics company also said that the tests show reduction time for initial treatment and new non-invasive genomic methods to cure accurate diagnosis. All the medical studies were verified and validated through the studies in collaboration with The Cleveland Clinic and Memorial Sloan-Kettering Cancer Center.
Panna Sharma, CEO of the Cancer Genetics said in a company statement that, this newest patent award received for our renal-cancer diagnostic fortifies our position and hard work in the attractive market of the medical segment. This further helps us cater more value for renal care providers and cancer patients. Nonetheless, the company is expecting the issuing of the patent and assigning of the patent number by January.